[go: up one dir, main page]

CL2009000965A1 - Oral tablet composed of a compound i comprising 10 to 20% by weight of the tablet or its pharmaceutically acceptable salt, which comprises in addition to a binding agent, a disintegrant, a diluent; tablet preparation process; and its use in the treatment of HIV and inflammatory diseases. - Google Patents

Oral tablet composed of a compound i comprising 10 to 20% by weight of the tablet or its pharmaceutically acceptable salt, which comprises in addition to a binding agent, a disintegrant, a diluent; tablet preparation process; and its use in the treatment of HIV and inflammatory diseases.

Info

Publication number
CL2009000965A1
CL2009000965A1 CL2009000965A CL2009000965A CL2009000965A1 CL 2009000965 A1 CL2009000965 A1 CL 2009000965A1 CL 2009000965 A CL2009000965 A CL 2009000965A CL 2009000965 A CL2009000965 A CL 2009000965A CL 2009000965 A1 CL2009000965 A1 CL 2009000965A1
Authority
CL
Chile
Prior art keywords
tablet
disintegrant
hiv
diluent
compound
Prior art date
Application number
CL2009000965A
Other languages
Spanish (es)
Inventor
Sheetal R Muley
Wing-Kee Philip Cho
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40910997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000965(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CL2009000965A1 publication Critical patent/CL2009000965A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Tableta oral compuesta por un compuesto i que comprende un 10 a 20% en peso de la tableta o su sal farmacéuticamente aceptable, que comprende además de un agente aglutinante, un desintegrante, un diluyente; proceso de preparación de la tableta; y su uso en el tratamiento de VIH y enfermedades inflamatorias.Oral tablet composed of a compound i that comprises 10 to 20% by weight of the tablet or its pharmaceutically acceptable salt, which also comprises a binding agent, a disintegrant, a diluent; tablet preparation process; and its use in the treatment of HIV and inflammatory diseases.

CL2009000965A 2008-04-28 2009-04-22 Oral tablet composed of a compound i comprising 10 to 20% by weight of the tablet or its pharmaceutically acceptable salt, which comprises in addition to a binding agent, a disintegrant, a diluent; tablet preparation process; and its use in the treatment of HIV and inflammatory diseases. CL2009000965A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4841108P 2008-04-28 2008-04-28

Publications (1)

Publication Number Publication Date
CL2009000965A1 true CL2009000965A1 (en) 2010-04-16

Family

ID=40910997

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000965A CL2009000965A1 (en) 2008-04-28 2009-04-22 Oral tablet composed of a compound i comprising 10 to 20% by weight of the tablet or its pharmaceutically acceptable salt, which comprises in addition to a binding agent, a disintegrant, a diluent; tablet preparation process; and its use in the treatment of HIV and inflammatory diseases.

Country Status (5)

Country Link
AR (1) AR071394A1 (en)
CL (1) CL2009000965A1 (en)
PE (1) PE20091886A1 (en)
TW (1) TW200948363A (en)
WO (1) WO2009134637A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020033283A1 (en) * 2018-08-09 2020-02-13 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc
CN113855640B (en) * 2021-11-21 2023-09-26 湖南洞庭药业股份有限公司 Solid pharmaceutical composition for treating mental diseases

Also Published As

Publication number Publication date
PE20091886A1 (en) 2009-12-19
TW200948363A (en) 2009-12-01
WO2009134637A1 (en) 2009-11-05
AR071394A1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
CY1119140T1 (en) COMPOSITION COMPOSITIONS AND METHODS OF CONSTRUCTION AND USE
ECSP088499A (en) NEW COMPOUNDS OF 2-AMINO-IMIDAZOL-4-ONA AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR USE IN THE TREATMENT OF COGNITIVE ALTERATION, ALZHEIMER'S DISEASE, NEURODEGENERATION AND DEMENTIA
CL2008003298A1 (en) Solid oral dosage form comprising a) a dual-acting compound in concentration between 4 and 90%, b) a pharmaceutically acceptable excipient; Preparation process; use in the treatment of cardiovascular and / or kidney diseases.
CL2007000789A1 (en) Malonamide derived compounds, gamma-secretase inhibitors; Preparation process; pharmaceutical composition; and its use in the treatment of Alzheimer's disease.
TW200637614A (en) Bendamustine pharmaceutical compositions
UY32062A (en) BETA-SECRETASA INHIBITORS
DOP2011000264A (en) AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
ECSP088974A (en) IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHEOSE QUINASA GLYCOGEN (GSK3)
MX2009001660A (en) 2,5-DIHYDROXIBENGEN COMPOUNDS FOR THE TREATMENT OF PSORIASIS.
PA8772101A1 (en) IMIDAZOL-TRIAZOLOPIRIMIDINAS REPLACED
UY33183A (en) INHIBITING COMPOUNDS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT
AR053162A1 (en) COMPOUND 5 - OXO - REPLACED PIRROLIDIN, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF GLAUCOMA.
PA8809601A1 (en) ANTI-RETROVIRAL COMBINATION
CU20120171A7 (en) SUBSTITUTED TRIAZOLOPIRIDINS
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
AR083150A1 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE HYDROMORPHONE AND NALOXONE
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
MX385354B (en) 3,6-DISUBSTITUTED XANTHYLUM SALTS.
AR050717A1 (en) PHARMACEUTICAL COMPOSITIONS
AR069508A1 (en) DERIVATIVES OF QUINOLINA 057; A PROCESS FOR PREPARATION; A PHARMACEUTICAL COMPOSITION; THE PREPARATION OF THIS AND THE USE OF THE COMPOUND TO PREPARE A MEDICINAL PRODUCT
GT200600163A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION
CL2008000738A1 (en) COMPOUNDS DERIVED FROM MALONAMIDE; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF DEPRESSION, PARKINSON AND ALZHEIMER'S DISEASE, BETWEEN OTHER DISEASES
MA32841B1 (en) Compounds of cyclondica dipseibeptides and their use as drugs
NO20076405L (en) Use of 24-nor-UDCA
CO6400226A2 (en) ANTI-INFLAMMATORY MICROLID